AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline cap US asthma inhaler monthly costs at $35, following insulin manufacturers' lead.
Drugmakers AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline will cap out-of-pocket costs for asthma inhalers at $35 per month, starting this Saturday. This follows similar steps taken by insulin manufacturers after the passage of the Inflation Reduction Act. The cost of inhalers in the US is significantly higher than in other wealthy countries; for example, AstraZeneca charges $645 in the US for an inhaler that costs $49 in the UK.
May 31, 2024
13 Articles